Aktis Oncology AKTS
NASDAQ AKTS
$16.62 +0.34 (+2.09%)
At close: Nov 13, 2026 · 4:00 PM EST

Aktis Oncology (AKTS) Gains (Losses) on Sale of Assets & Investments (2025 - 2026)

Updated

Aktis Oncology (AKTS) reported Gains (Losses) on Sale of Assets & Investments of -$1.18 million for Q3 2026, compared with $30,000 a year earlier.

Analysis

Aktis Oncology (AKTS) Gains (Losses) on Sale of Assets & Investments (2025 - 2026) Analysis & Trends

Over the twelve months ended Sep 30, 2026, Aktis Oncology's Gains (Losses) on Sale of Assets & Investments came in at -$1.95 million; for FY2025, it came in at -$82,000.

  • By year, Gains (Losses) on Sale of Assets & Investments came in at $42,000 in FY2024.
  • Per Business Quant data, the three quarters before Q3 2026 came in at -$504,000 (Q2 2026), -$283,000 (Q1 2026) and $26,000 (Q4 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Gains on Sales (Qtr)
1 Eli Lilly 1,359.75 Bn 1,333.37 Bn 20.46 Bn -
2 Johnson & Johnson 688.76 Bn 608.62 Bn 17.30 Bn -
3 AbbVie 521.69 Bn 489.75 Bn 13.12 Bn -
4 Merck 364.31 Bn 327.31 Bn 13.19 Bn -
5 Novartis Ag 306.35 Bn 279.93 Bn - -
6 Astrazeneca 285.96 Bn 259.56 Bn 13.26 Bn -
7 Amgen 251.88 Bn 203.53 Bn 7.58 Bn -
8 Gilead Sciences 208.59 Bn 183.61 Bn 6.73 Bn -
9 Pfizer 164.73 Bn 112.38 Bn 12.56 Bn -
10 Aktis Oncology 895.95 Mn 335.72 Mn - -1.18 Mn
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 -1.18 Mn
Jun 30, 2026 -504,000.00
Mar 31, 2026 -283,000.00
Jun 30, 2025 -80,000.00
Mar 31, 2025 -58,000.00
API Access

Aktis Oncology Gains (Losses) on Sale of Assets & Investments API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-operating-investment-income&ticker=AKTS&period=max&api_key=YOUR_API_KEY